Updates are available Correction dated 2024-09-04
Click to view Correction: https://doi.org/10.1186/s13059-024-03387-4
-
Authors
Vinceti, Alessandro https://orcid.org/0000-0001-8993-9636
Iannuzzi, Raffaele M. https://orcid.org/0000-0003-2885-6823
Boyle, Isabella https://orcid.org/0000-0002-8138-1225
Trastulla, Lucia https://orcid.org/0000-0001-8749-475X
Campbell, Catarina D. https://orcid.org/0000-0002-3863-9841
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
Dempster, Joshua M. https://orcid.org/0000-0002-3634-9576
Iorio, Francesco https://orcid.org/0000-0001-7063-8913
-
Funding
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (28772)
HORIZON EUROPE European Research Council (101125051)
- License Information
-
More Information
Article History
Received: 12 January 2024
Accepted: 10 July 2024
First Online: 19 July 2024
Change Date: 4 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13059-024-03387-4
Declarations
:
: Not applicable.
: Not applicable.
: FI receives funding from Open Targets, a public-private initiative involving academia and industry and performs consultancy for the joint CRUK-AstraZeneca Functional Genomics Centre and for Mosaic TX. JD is a consultant for and holds equity in Jumble Therapeutics. CDC performs consultancy for Droplet Biosciences and is a shareholder of Novartis. FV receives research support from the Dependency Map Consortium, Riva Therapeutics, Bristol Myers Squibb, Merck, Illumina, and Deerfield Management. FV is on the scientific advisory board of GSK, is a consultant and holds equity in Riva Therapeutics and is a co-founder and holds equity in Jumble Therapeutics. All other authors declare that they have no competing interests.
